{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:37:59Z","timestamp":1769193479157,"version":"3.49.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,15]]},"DOI":"10.2146\/ajhp120131","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T11:33:50Z","timestamp":1372764830000},"page":"1219-1225","source":"Crossref","is-referenced-by-count":56,"title":["Fenofibrate-associated nephrotoxicity: A review of current evidence"],"prefix":"10.1093","volume":"70","author":[{"given":"Rebecca L.","family":"Attridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurajo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Koeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Linn","sequence":"additional","affiliation":[{"name":"Rebecca L. Attridge, Pharm.D., M.Sc., is Assistant Professor, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX, and Adjunct Assistant Professor, University of Texas Health Science Center (UTHSC), San Antonio. Christopher R. Frei, Pharm.D., M.Sc., is Associate Professor; LaurajoRyan, Pharm.D., M.Sc., is Clinical Associate Professor; and JimKoeller, M.Sc., is Professor, Co"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019031300562901500_b1-0701219","unstructured":"Veterans Administration for Medication Safety. Adverse drug events, adverse drug reactions, and medication errors: frequently asked questions. www.pbm.va.gov\/vamedsafe\/Adverse%20Drug%20Reaction.pdf (accessed 2011 Sep 7)."},{"key":"key\n\t\t\t\t2019031300562901500_b2-0701219","doi-asserted-by":"crossref","first-page":"ITC9-1","DOI":"10.7326\/0003-4819-147-5-200709040-01009","article-title":"In the clinic. Dyslipidemia","volume":"147","author":"Laine","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019031300562901500_b3-0701219","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1592\/phco.27.3.412","article-title":"Fibrates: what have we learned in the past 40 years?","volume":"27","author":"Backes","year":"2007","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019031300562901500_b4-0701219","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-200767010-00013","article-title":"Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus","volume":"67","author":"Keating","year":"2007","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019031300562901500_b5-0701219","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CRD.0b013e31816b43d3","article-title":"Fibrate therapy: an update","volume":"16","author":"Remick","year":"2008","journal-title":"Cardiol Rev"},{"key":"key\n\t\t\t\t2019031300562901500_b6-0701219","volume-title":"TriCor (fenofibrate) package insert","year":"2011"},{"key":"key\n\t\t\t\t2019031300562901500_b7-0701219","volume-title":"Antara (fenofibrate) package insert","year":"2009"},{"key":"key\n\t\t\t\t2019031300562901500_b8-0701219","volume-title":"Triglide (fenofibrate) package insert","year":"2011"},{"key":"key\n\t\t\t\t2019031300562901500_b9-0701219","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0272-6386(04)00832-7","article-title":"Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity","volume":"44","author":"Angeles","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019031300562901500_b10-0701219","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-5-20","article-title":"Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes mellitus: therapeutic options beyond statins","volume":"5","author":"Tenenbaum","year":"2006","journal-title":"Cardiovasc Diabetol"},{"key":"key\n\t\t\t\t2019031300562901500_b11-0701219","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2796.2007.01892.x","article-title":"Peroxisome proliferator-activated receptors\u2014from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease","volume":"263","author":"Bouhlel","year":"2008","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t2019031300562901500_b12-0701219","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/ATVBAHA.107.148817","article-title":"Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?","volume":"28","author":"Barter","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t2019031300562901500_b13-0701219","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clinthera.2007.05.002","article-title":"Hypertriglyceridemia and cardiovascular risk reduction","volume":"29","author":"Jacobson","year":"2007","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019031300562901500_b14-0701219","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects, and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t2019031300562901500_b15-0701219","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031300562901500_b16-0701219","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031300562901500_b17-0701219","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031300562901500_b18-0701219","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019031300562901500_b19-0701219","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/ndt\/15.12.1993","article-title":"Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?","volume":"15","author":"Broeders","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019031300562901500_b20-0701219","first-page":"39","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"Lipscombe","year":"2001","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t2019031300562901500_b21-0701219","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1592\/phco.21.13.1145.34623","article-title":"Fenofibrate-induced elevation in serum creatinine","volume":"21","author":"Ritter","year":"2001","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019031300562901500_b22-0701219","first-page":"337","article-title":"Fenofibrate can increase serum creatinine levels in renal insufficiency","volume":"54","author":"Paul","year":"2006","journal-title":"J Assoc Physicians India"},{"key":"key\n\t\t\t\t2019031300562901500_b23-0701219","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2146\/ajhp070005","article-title":"Elevated serum creatinine levels associated with fenofibrate therapy","volume":"65","author":"McQuade","year":"2008","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019031300562901500_b24-0701219","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2011.08.008","article-title":"Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity","volume":"6","author":"Attridge","year":"2012","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t2019031300562901500_b25-0701219","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"key\n\t\t\t\t2019031300562901500_b26-0701219","first-page":"41","article-title":"Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency","volume":"20","author":"Hottelart","year":"1999","journal-title":"Nephrologie"},{"key":"key\n\t\t\t\t2019031300562901500_b27-0701219","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/dc09-0621","article-title":"Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy","volume":"33","author":"Forsblom","year":"2010","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019031300562901500_b28-0701219","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","article-title":"Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials","volume":"297","author":"Nissen","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019031300562901500_b29-0701219","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019031300562901500_b30-0701219","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"25","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019031300562901500_b31-0701219","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00125-012-2524-2","article-title":"Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience","volume":"55","author":"Bonds","year":"2012","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t2019031300562901500_b32-0701219","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019031300562901500_b33-0701219","first-page":"407","article-title":"Possible mechanisms of the fibrate-induced increase in serum creatinine","volume":"57","author":"Tsimihodimos","year":"2002","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t2019031300562901500_b34-0701219","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019031300562901500_b35-0701219","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/MCC.0b013e3280102af7","article-title":"Acute kidney injury: epidemiology and diagnostic criteria","volume":"12","author":"Hoste","year":"2006","journal-title":"Curr Opin Crit Care"},{"key":"key\n\t\t\t\t2019031300562901500_b36-0701219","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/14\/1219\/28050657\/ajhp1219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T16:36:09Z","timestamp":1715618169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/14\/1219\/5112254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,15]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2013,7,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120131","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,7,15]]},"published":{"date-parts":[[2013,7,15]]}}}